-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 26, the NMPA official website updated the drug approval document information, and Qilu Pharmaceutical's Granisetron Hydrochloride Injection was the first to pass the consistency evaluation.
Figure 1: Qilu Pharmaceutical's over-rated product information
Source: NMPA official website
Granisetron is a highly selective 5-HT3 receptor antagonist, suitable for the prevention and treatment of nausea and vomiting caused by tumor radiotherapy and chemotherapy.
Table 1: Antiemetics and anti-nausea drugs that have been reviewed/deemed to have been reviewed earlier
Source: Meinenet MED2.
Note: *is the first company to pass the evaluation
According to data from Minei.
Table 2: 2020H1 Qilu's ranking of antiemetics and antinausea brands
Source: Mi Nei.
According to the comprehensive database of the MID Drug Index of Meinenet, Qilu has 7 products related to antiemetics and anti-nausea drugs, 4 of which have entered the TOP20 brand list of terminal antiemetics and anti-nausea drugs in China's public medical institutions in the first half of 2020.
Source: Mi Nei.
The review data statistics are as of April 26, if there are any errors or omissions, please correct me.